An investor group including Pernix Therapeutics Holdings, a publicly traded developer of pain and neurological drugs, won court approval to buy Orexigen Therapeutics out of bankruptcy for $75 million.

San Diego’s Orexigen Therapeutics, maker of a weight-loss drug that had once promised to improve the treatment of obesity, has agreed to sell its assets for $75 million cash. The buyer is ...

Orexigen Therapeutics Inc., the publicly traded maker of anti-obesity drug Contrave, said Monday it plans to sell itself through a chapter 11 bankruptcy proceeding. Orexigen cited a missed 2017 ...

Orexigen Therapeutics is filing for bankruptcy and plans to auction off its obesity med, Contrave, to pay down its debt. The San Diego-based company filed for a voluntary petition under Chapter 11 ...

Drugmaker Orexigen Therapeutics Inc <OREX.O> said on Monday it filed for Chapter 11 bankruptcy protection and will also file a motion to pursue an auction and sale process of substantially all its ...

RELATED: Orexigen's post-Takeda plans for Contrave don't include 2016 growth With those performances in mind, it’ll take a lot to convince a potential buyer that it can turn the market around.

* Orexigen Therapeutics - if approved, Valeant will market and distribute Contrave in Canada as part of its distributorship agreement with Orexigen Source text for Eikon: Further company coverage ...

At the time, Orexigen had no products in the market, so all its hopes of financial success rested on this new treatment. Contrave had proven to be highly effective in clinical trials, and Orexigen ...

Orexigen is also required to pay Takeda milestone payments upon achievement of certain levels of U.S. net sales of Contrave. The first such payment, totaling $10 million, will occur when Contrave ...

Orexigen Therapeutics has announced receipt of the first of three potential $15 million anniversary milestone payments from Takeda Pharmaceuticals.

Trade-Ideas LLC identified Orexigen Therapeutics (OREX) as a weak on high relative volume candidate ...

Orexigen Therapeutics suffers a double-whammy in August, and its shares lose more than 30% of their value as a result. Is now the time to consider Orexigen a bargain?